PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 80 mg PF-06473871Drug: 160 mg PF-06473871Drug: 320 mg PF-06473871Drug: 480 mg PF-06473871
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT01753791
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01749085
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Users Study Of The Caverject Delivery System
Early Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: dual-chamber syringe
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01747928
- Locations
- πΊπΈ
Vince and Associates Clinical Research, Overland Park, Kansas, United States
Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01747941
- Locations
- π§πͺ
Pfizer Investigational Site, Brussels, Belgium
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: intact ALO-02 60 mg/7.2 mgDrug: crushed ALO-02 60 mg/7.2 mgDrug: crushed ALO-02 40 mg/4.8 mg
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT01746901
- Locations
- π¨π¦
INC Research Toronto, Inc., Toronto, Ontario, Canada
Co-Administration Of Methotrexate And CP-690,550
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: CP-690,550 (tofacitinib)
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01745055
- Locations
- πΊπΈ
Pfizer Investigational Site, Dallas, Texas, United States
CP-690,550 Thorough QTc Study
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT01743677
- Locations
- πΈπ¬
Pfizer Clinical Research Unit, Singapore, Singapore
A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboBiological: PF-06342674 Dose ABiological: PF-06342674 Dose BBiological: PF-06342674 Dose CBiological: PF-06342674 Dose DBiological: PF-06342674 Dose EBiological: PF-06342674 Dose FBiological: PF-06342674 Dose GBiological: PF-06342674 Dose HBiological: PF-06342674 Dose IBiological: PF-06342674 Dose J
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT01740609
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01740362
- Locations
- πΊπΈ
Pfizer Investigational Site, Minneapolis, Minnesota, United States
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 666
- Registration Number
- NCT01740427
- Locations
- πΊπΈ
Translational Research Management, Los Angeles, California, United States
πΊπΈUCLA West Medical Pharmacy: Drug Management Only, Los Angeles, California, United States
πΊπΈUCLA West Medical Pharmacy, Los Angeles, California, United States